• Alias: BAY 86-9766, RDEA119
    • Highly selective, orally bioavailable inhibitor of MEK 1/2
    • Currently in phases 1 and 2 clinical trials for advanced cancers such as pancreatic cancer and HCC
    • Recommended dose: 100 mg PO daily
    • Half-life: â™12 hours
    • Metabolism: Substrates of CYP3A4 and CYP2C19; concomitant use of inhibitors or inducers of these enzymes should be avoided.
    • Common side effects: Acneiform dermatitis, diarrhea, nausea/vomiting, lymphedema, fatigue, rash
    (Weekes et al., 2013)
    Other topics in Targeted and Immunotherapy Agents